Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Sumitomo Dainippon Pharma Co., Ltd.
  6. Summary
    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO., LTD.

(4506)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
2062 2066 2053 2080 2116 Last
466000 721400 542200 702200 1434700 Volume
-1.01% +0.19% -0.63% +1.32% +1.73% Change
Estimated financial data (e)
Sales 2022 575 B 5 231 M 5 231 M
Net income 2022 49 697 M 452 M 452 M
Net Debt 2022 42 797 M 389 M 389 M
P/E ratio 2022 16,1x
Yield 2022 1,32%
Sales 2023 584 B 5 313 M 5 313 M
Net income 2023 49 338 M 449 M 449 M
Net Debt 2023 19 950 M 181 M 181 M
P/E ratio 2023 16,7x
Yield 2023 1,32%
Capitalization 841 B 7 650 M 7 647 M
EV / Sales 2022 1,54x
EV / Sales 2023 1,47x
Nbr of Employees 6 822
Free-Float 40,0%
More Financials
Company
Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other Overseas division is involved in the development of its products in... 
More about the company
Ratings of Sumitomo Dainippon Pharma Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SUMITOMO DAINIPPON PHARMA CO., LTD.
09/13Poxel Announces Product Launch in Japan for TWYMEEG as Treatment for Type 2 D..
AQ
09/10Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYM..
CI
09/09SUMITOMO DAINIPPON PHARMA : Announces Launch of TWYMEEG for the Treatment of Typ..
PU
09/08NABRIVA THERAPEUTICS' : Xenleta Receives Approval in Taiwan to Treat Community-A..
MT
09/07SUMITOMO DAINIPPON PHARMA : Posted Presentation Material (Frontier Business Meet..
PU
09/07SUMITOMO DAINIPPON PHARMA : Sep. 08, 2021 Frontier Business Meeting - FBO Showca..
PU
09/06SUMITOMO DAINIPPON PHARMA : and Pixie Dust Technologies Sign Joint R&D Agreement..
AQ
09/02SUMITOMO DAINIPPON PHARMA : and Pixie Dust Technologies Sign Joint R&D Agreement..
PU
09/02SUMITOMO DAINIPPON PHARMA : Sunovion and BIAL Enter European Licensing Agreement..
PU
08/26SUMITOMO DAINIPPON PHARMA : Jul. 29, 2021 Q1 FY2021 Conference Call transcript(P..
PU
08/19SUMITOMO DAINIPPON PHARMA : Announces Transfer of Shares of its Indirectly-Owned..
AQ
08/05SUMITOMO DAINIPPON PHARMA : Listed Continuously in FTSE4Good Index Series and FT..
AQ
08/04C4U Co., Ltd. announced that it has received ą930 million in funding from TAU..
CI
08/04SUMITOMO DAINIPPON PHARMA : Listed Continuously in FTSE4Good Index Series and FT..
PU
07/30NIKKEI 225 : Dow 1.8% on Pandemic Outlook, Yen Strength
MT
More news
News in other languages on SUMITOMO DAINIPPON PHARMA CO., LTD.
09/10POXEL : premier lancement commercial au Japon
09/08Le Xenleta de Nabriva Therapeutics est approuvé à Taïwan pour le traitement d..
07/22POXEL : une trésorerie de à 36,9 millions d'euros fin juin
06/23POXEL : le titre en hausse après un feu vert au Japon
05/03La biotech Roivant entre en bourse via le SPAC Montes Archimedes
More news
Chart SUMITOMO DAINIPPON PHARMA CO., LTD.
Duration : Period :
Sumitomo Dainippon Pharma Co., Ltd. Technical Analysis Chart | 4506 | JP3495000006 | MarketScreener
Technical analysis trends SUMITOMO DAINIPPON PHARMA CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 2 116,00 JPY
Average target price 1 837,78 JPY
Spread / Average Target -13,1%
EPS Revisions
Managers and Directors
Hiroshi Nomura President, Chief Executive Officer & Director
Masayo Tada Chairman
Yoshiharu Ikeda GM-Production, Head-Research & Technology
Yutaka Atomi Independent Outside Director
Saeko Arai Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
SUMITOMO DAINIPPON PHARMA CO., LTD.38.94%7 650
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604